Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03436615 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
A Phase 2 study, sponsored by Novan.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
NCT03436615 is a Phase 2 study that has completed, run by Novan. The registered enrollment target is 256 participants.
The verdict
NCT03436615, a Phase 2 study, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
Study Summary
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
Interventions
- DRUG Placebo
- DRUG SB206 4%
- DRUG SB206 8%
- DRUG SB206 12%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2018-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03436615
The ClinicalTrials.gov registry entry for NCT03436615 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03436615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03436615 about?
NCT03436615 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum". This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
What is the current status of trial NCT03436615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2018-01-24. Estimated completion is 2018-11-03.
What interventions are being tested in trial NCT03436615?
The interventions under investigation include: Placebo (DRUG), SB206 4% (DRUG), SB206 8% (DRUG), SB206 12% (DRUG).
Who is sponsoring clinical trial NCT03436615?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.